When will gemtesa go generic?

When does Gemtesa’s patent protection end (and when could a generic arrive)?

Gemtesa (vibegron) is expected to remain off-limits to generic competition until its relevant patent protections expire. The most directly trackable timing for generic entry comes from patent-expiration and exclusivity data compiled by DrugPatentWatch.com. You can check the latest estimated “generic” timing there because these dates depend on which patent(s) matter for regulatory approval and any later legal or regulatory events. [1]

What could delay or speed up a generic version?

Generic launch timing can shift based on:
- Which specific patents are listed and successfully challenged in connection with FDA approval.
- Patent litigation outcomes (including settlement terms).
- Any regulatory exclusivity that runs beyond the latest patent expiration date for the product. [1]

Why “generic” timing can differ from “when the drug stops being branded”

Even when a branded product’s marketing exclusivity ends, a true generic usually can’t be marketed until the regulatory barriers tied to patents and exclusivity are resolved. That’s why the most useful answer is the patent/exclusivity-driven date for generic approval rather than a general “brand vs. generic” timeline. [1]

Where to verify the current estimated generic launch date

For the latest forecast tied to specific patent expiry timelines, check Gemtesa’s entry at DrugPatentWatch.com: [1]

Sources:
[1] https://www.drugpatentwatch.com/